Last reviewed · How we verify
hyaluronidase powder
At a glance
| Generic name | hyaluronidase powder |
|---|---|
| Also known as | Omnidase 1500iu Injection, Hirax Inj® BMI KOREA Pharmaceutical, South Korea |
| Sponsor | Kasr El Aini Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effect of Local Use of Non-steroidal Anti-inflammatory Agent (Diclofenac Sodium) With and Without Hyaluronidase on Post-surgical Pain and Swelling (NA)
- Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer (PHASE3)
- Efficacy and Safety of Adding Atracurium to Percaruncular Block for High Myopes Undergoing Cataract Surgery (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hyaluronidase powder CI brief — competitive landscape report
- hyaluronidase powder updates RSS · CI watch RSS
- Kasr El Aini Hospital portfolio CI